These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 10328593)

  • 21. Cetuximab plus radiotherapy for head and neck cancer.
    Cengiz M; Yildiz F; Genc M
    N Engl J Med; 2006 May; 354(20):2187; author reply 2187. PubMed ID: 16710908
    [No Abstract]   [Full Text] [Related]  

  • 22. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
    Herbst RS; Hong WK
    Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas.
    Clin Adv Hematol Oncol; 2007 Feb; 5(2):79-81. PubMed ID: 17344795
    [No Abstract]   [Full Text] [Related]  

  • 24. Head and neck cancer: integrating anti-EGFR treatment with standard therapy.
    Kies MS
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S52-9. PubMed ID: 19780246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging drugs for head and neck cancer.
    Rhee JC; Khuri FR; Shin DM
    Expert Opin Emerg Drugs; 2004 May; 9(1):91-104. PubMed ID: 15155138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck.
    Burtness B
    J Clin Oncol; 2005 Aug; 23(24):5440-2. PubMed ID: 16009959
    [No Abstract]   [Full Text] [Related]  

  • 27. Molecularly targeted therapies in head and neck cancers.
    Sawicki M; Szudy A; Szczyrek M; Krawczyk P; Klatka J
    Otolaryngol Pol; 2012; 66(5):307-12. PubMed ID: 23036118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Promising new advances in head and neck radiotherapy.
    Harari PM
    Ann Oncol; 2005; 16 Suppl 6():vi13-vi19. PubMed ID: 15987991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
    Bozec A; Peyrade F; Milano G
    Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Cetuximab in combination with radiotherapy or chemotherapy against advanced squamous cell carcinoma of the head and neck.
    Li JZ; Zheng JW; Zhang ZY
    Shanghai Kou Qiang Yi Xue; 2008 Feb; 17(1):1-5. PubMed ID: 18360658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of combined treatment with cetuximab (erbitux) and radiation therapy in patients with head and neck cancer.
    Koukourakis G; Kouloulias V; Koukourakis M; Kouvaris J; Zacharias G; Gouliamos A
    J BUON; 2009; 14(1):19-25. PubMed ID: 19373942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.
    Baselga J; Pfister D; Cooper MR; Cohen R; Burtness B; Bos M; D'Andrea G; Seidman A; Norton L; Gunnett K; Falcey J; Anderson V; Waksal H; Mendelsohn J
    J Clin Oncol; 2000 Feb; 18(4):904-14. PubMed ID: 10673534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accelerated fractionated irradiation with simultaneous cisplatin infusion in advanced head and neck cancer.
    Karstens JH; Hermes H; Schnarkowski P; Ammon J
    Onkologie; 1989 Aug; 12(4):187-9. PubMed ID: 2677879
    [No Abstract]   [Full Text] [Related]  

  • 35. Cetuximab plus radiotherapy for head and neck cancer.
    Ho AC
    N Engl J Med; 2006 May; 354(20):2187; author reply 2187. PubMed ID: 16707760
    [No Abstract]   [Full Text] [Related]  

  • 36. Targeting ErbB-1 and ErbB-4 in irradiated head and neck cancer: results of in vitro and in vivo studies.
    Barnea I; Haif S; Keshet R; Karaush V; Lev-Ari S; Khafif A; Shtabsky A; Yarden Y; Vexler A; Ben Yosef R
    Head Neck; 2013 Mar; 35(3):399-407. PubMed ID: 22367849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
    Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
    J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?
    Bourhis J; Lefebvre JL; Vermorken JB
    Eur J Cancer; 2010 Jul; 46(11):1979-89. PubMed ID: 20561781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular therapy in head and neck oncology.
    Bernier J; Bentzen SM; Vermorken JB
    Nat Rev Clin Oncol; 2009 May; 6(5):266-77. PubMed ID: 19390553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results.
    Adelstein DJ; Saxton JP; Lavertu P; Tuason L; Wood BG; Wanamaker JR; Eliachar I; Strome M; Van Kirk MA
    Head Neck; 1997 Oct; 19(7):567-75. PubMed ID: 9323144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.